Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enfamil LIPIL adds soy

This article was originally published in The Tan Sheet

Executive Summary

Enfamil ProSobee LIPIL - soy infant formula fortified with nutritional oils DHA, ARA - began shipping Dec. 3, Mead Johnson says. ProSobee will be available in ready-to-use, powder, concentrate forms, BMS division says. As with other LIPIL products, ProSobee is priced 15% higher than non-fortified formulas. Ross Products also plans to launch a fortified soy formula this month (1"The Tan Sheet" Nov. 4, 2002, In Brief)...

You may also be interested in...



Isomil extension

Isomil Advance soy infant formula supplemented with DHA, ARA oils will reach shelves in December, Ross Products announces Oct. 28. Advance "for babies with feeding sensitivities" is "first and only soy formula" in the U.S. supplemented with docosahexaenoic, arachidonic acid nutritional oils, Ross says. Formula will be available in 12.9 oz. and 25.7 oz. powders, 32 oz. ready-to-feed resealable bottles, 13 oz. concentrated liquid, and carries SRP slightly higher than non-fortified formulations, Abbott Labs division notes...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS094872

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel